HPP 854

Drug Profile

HPP 854

Alternative Names: HPP854; TTP-854

Latest Information Update: 31 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TransTech Pharma
  • Developer High Point Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 10 Sep 2014 No development reported - Phase-I for Alzheimer's disease in USA (PO)
  • 31 Aug 2012 High Point Pharmaceuticals terminates phase I trial in Alzheimer's disease in USA (NCT01482013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top